BLPH VS NBY Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

NBY
10/100

NBY returned -88.00% in the last 12 months. Based on SPY's performance of -13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

NBY
75/100

4 analysts offer 12-month price targets for NBY. Together, they have an average target of 0, the most optimistic target put NBY at 0 within 12-months and the most pessimistic has NBY at 0.

Technicals

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

NBY
21/100

NBY receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

NBY
10/100

NBY has missed earnings 9 times in the last 20 quarters.

Profit

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

NBY
10/100

Out of the last 20 quarters, NBY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

NBY
58/100

NBY has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH
Healthcare
Biotechnology
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

NovaBay Pharmaceuticals, Inc. Summary

Healthcare
Biotechnology
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.